Identification of Novel in Vivo Raf-1 Phosphorylation Sites Mediating Positive Feedback Raf-1 Regulation by Extracellular Signal-regulated Kinase
Overview
Molecular Biology
Authors
Affiliations
The Ras-Raf-mitogen-activated protein kinase cascade is a key growth-signaling pathway, which uncontrolled activation results in transformation. Although the exact mechanisms underlying Raf-1 regulation remain incompletely understood, phosphorylation has been proposed to play a critical role in this regulation. We report here three novel epidermal growth factor-induced in vivo Raf-1 phosphorylation sites that mediate positive feedback Raf-1 regulation. Using mass spectrometry, we identified Raf-1 phosphorylation on three SP motif sites: S289/S296/S301 and confirmed their identity using two-dimensional-phosphopeptide mapping and phosphospecific antibodies. These sites were phosphorylated by extracellular signal-regulated kinase (ERK)-1 in vitro, and their phosphorylation in vivo was dependent on endogenous ERK activity. Functionally, ERK-1 expression sustains Raf-1 activation in a manner dependent on Raf-1 phosphorylation on the identified sites, and S289/296/301A substitution markedly decreases the in vivo activity of Raf-1 S259A. Importantly, the ERK-phosphorylated Raf-1 pool has 4 times higher specific kinase activity than total Raf-1, and its phosphopeptide composition is similar to that of the general Raf-1 population, suggesting that the preexisting, phosphorylated Raf-1, representing the activatable Raf-1 pool, is the Raf-1 subpopulation targeted by ERK. Our study describes the identification of new in vivo Raf-1 phosphorylation sites targeted by ERK and provides a novel mechanism for a positive feedback Raf-1 regulation.
Tsai Y, Fang M, Chen C, Yu I, Shun C, Tao M Commun Biol. 2024; 7(1):1672.
PMID: 39702454 PMC: 11659619. DOI: 10.1038/s42003-024-07357-1.
Hoermann B, Durr E, Ludwig C, Ercan M, Kohn M Chem Sci. 2024; 15(8):2792-2804.
PMID: 38404380 PMC: 10882499. DOI: 10.1039/d3sc04746f.
The role of CRAF in cancer progression: from molecular mechanisms to precision therapies.
Riaud M, Maxwell J, Soria-Bretones I, Dankner M, Li M, Rose A Nat Rev Cancer. 2024; 24(2):105-122.
PMID: 38195917 DOI: 10.1038/s41568-023-00650-x.
Phenotype Switching and the Melanoma Microenvironment; Impact on Immunotherapy and Drug Resistance.
Hossain S, Eccles M Int J Mol Sci. 2023; 24(2).
PMID: 36675114 PMC: 9864717. DOI: 10.3390/ijms24021601.
Qian Y, Zhou L, Luk S, Xu J, Li W, Gou H Oncogene. 2022; 42(8):601-612.
PMID: 36564468 PMC: 9937924. DOI: 10.1038/s41388-022-02576-4.